Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226704 | 1.00 | FAAH (0.54) | FAAHCA2RELAPPARATSHR | |
| SCHEMBL301013 | 0.97 | FAAH (0.50) | FAAHCA2RELAKDM4EHPGD | |
| SCHEMBL14932179 | 0.95 | FAAH (0.50) | FAAHCA2RELAPPARAKDM4E | |
| SCHEMBL15958664 | 0.92 | FAAH (0.46) | FAAHCA2RELAKDM4EHPGD | |
| SCHEMBL239451 | 0.89 | HPGD (0.44) | FAAHCA2RELAPPARAKDM4E | |
| SCHEMBL3030769 | 0.88 | FAAH (0.48) | FAAHCA2RELAPPARAKDM4E | |
| SCHEMBL25834178 | 0.88 | FAAH (0.48) | FAAHCA2RELAPPARAKDM4E | |
| SCHEMBL12386317 | 0.88 | FAAH (0.48) | FAAHCA2RELAPPARAKDM4E | |
| SCHEMBL25834184 | 0.88 | FAAH (0.48) | FAAHCA2RELAPPARAKDM4E | |
| SCHEMBL8468253 | 0.86 | FAAH (0.46) | FAAHCA2RELAPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105473542-B | The manufacturing method of optical activity 5- hydroxyl -3- ketone ester class | 日产化学工业株式会社 | 2018-12-04 | — | — | CN | disclosed |
| US-9897922-B2 | Method of forming pattern and developer for use in the method | FUJIFILM CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | FAAH 543/4885CA2 3850/4885RELA 1319/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | FAAH 405/4885CA2 1990/4885RELA 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.